MohamadAHusseinMD

Oncology • Tampa, FL

Hematologic Oncology

Physician

Join to view full profile

Dr. Hussein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hussein's full profile

Already have an account?

Office
13330 Usf Laurel Dr
Tampa, FL 33612
Phone+1 813-974-2201
Is this information wrong?

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1986 - 1989
Cleveland Clinic FoundationResidency, Internal Medicine, 1985 - 1986
University of Mississippi Medical CenterResidency, Internal Medicine, 1983 - 1985
Ain Shams University Faculty of MedicineClass of 1981

Certifications & Licensure

FL State Medical License 2007 - 2025
OH State Medical License 1986 - 2024
MD State Medical License 1989 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013

Clinical Trials

Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma Start of enrollment: 1998 Oct 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Multiple Myeloma Start of enrollment: 1998 Nov 01
Completed
Phase 2
Rituximab in Treating Patients With Multiple Myeloma Start of enrollment: 1998 Nov 01
Completed
Phase 2
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2000 Mar 09
Completed
Phase 3
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma Start of enrollment: 2000 Apr 01
Terminated
Phase 3
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2002 Jun 01
Completed
Phase 2
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Withdrawn
Phase 2
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Aug 01
Terminated
Phase 2
Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2006 Mar 01
Completed
Phase 2
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2016 Jul 11
Terminated
Phase 1
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) Start of enrollment: 2017 Jan 05
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

59 citations
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials
Sikander Ailawadhi, Susanna Jacobus, Rachael Sexton, Alexander Keith Stewart, Angela Dispenzieri, Mohamad A. Hussein, Jeffrey A. Zonder, John Crowley, Antje Hoering, B...> ;Blood Cancer Journal. 2018 Jul 6
64 citations
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2017 Aug 1
Response to letter, ‘Immortal time bias in retrospective analysis’
Meletios A. Dimopoulos, Arlene S. Swern, Jack Shiansong Li, Mohamad A. Hussein, Lilia Weiss, Yasir Nagarwala, Rachid Baz> ;Blood Cancer Journal. 2015 Jul 31
31 citations
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma
Steven R. Arikian, Dejan Milentijevic, Gary Binder, Craig J. Gibson, X. Henry Hu, Yasir Nagarwala, Mohamad A. Hussein, Frank A. Corvino, Andy Surinach, Saad Z. Usmani> ;Current Medical Research and Opinion. 2015 Mar 18
8 citations
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludara...
David M. Lucas, Amy S. Ruppert, Gerard Lozanski, Gordon W. Dewald, Arletta Lozanski, Rainer Claus, Christoph Plass, Ian W. Flinn, Donna Neuberg, Elisabeth Paietta, Joh...> ;Leukemia & Lymphoma. 2015 Feb 27
36 citations
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios A. Dimopoulos, Arlene S. Swern, Jack Shiansong Li, Mohamad A. Hussein, Lilia Weiss, Yasir Nagarwala, Rachid Baz> ;Blood Cancer Journal. 2014 Nov 7
27 citations
Quantification of peptides from immunoglobulin constant and variable regions by LC‐MRM MS for assessment of multiple myeloma patients
Elizabeth R. Remily-Wood, Kaaron Benson, Rachid Baz, Y. Ann Chen, Mohamad A. Hussein, Monique A. Hartley-Brown, Robert Sprung, Brianna Perez, Richard Z. Liu, Sean J. Y...> ;Proteomics. Clinical Applications. 2014 Oct 1
18 citations
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434
Gordan Srkalovic, Mohamad A. Hussein, Antje Hoering, Jeffrey A. Zonder, Leslie Popplewell, Harsha Trivedi, Sandy Mazzoni, Rachel Sexton, Robert Z. Orlowski, Bart Barlogie> ;Cancer Medicine. 2014 Oct 1
8 citations
Phase II study of pegylated liposomal doxorubicin, low‐dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
Rachid Baz, Kenneth H. Shain, Mohamad A. Hussein, Ji-Hyun Lee, Daniel M. Sullivan, Elizabeth Finley Oliver, Lisa A. Nardelli, Lisa A. Nodzon, Xiuhua Zhao, Jose L. Ocho...> ;American Journal of Hematology. 2014 Jan 1
8 citations
Mature results of MM‐011: A phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide mainte...
Aleksandr Lazaryan, Mohamad A. Hussein, Frederic J. Reu, Beth Faiman, Becky Habecker, Mary Ann Karam, Janice Reed, Kimberly Hamilton, Joel Waksman, Kellie Bruening, Go...> ;American Journal of Hematology. 2014 Apr 1
25 citations
Total cost comparison in relapsed/refractory multiple myeloma
Brian G.M. Durie, Gary Binder, Chris L. Pashos, Zeba M. Khan, Mohamad A. Hussein, Ivan Borrello> ;Journal of Medical Economics. 2013 Jan 3
42 citations
Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
Donna M. Weber, Thorsten Graef, Mohamad A. Hussein, Ronald Sobecks, Gary J. Schiller, Lisa Lupinacci, James S. Hardwick, Sundar Jagannath> ;Clinical Lymphoma, Myeloma & Leukemia. 2012 Oct 1
20 citations
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma.
Meletios A. Dimopoulos, Mohamad A. Hussein, Arlene S. Swern, Donna M. Weber> ;Leukemia. 2011 Oct 1
32 citations
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term f...
Mitchell R. Smith, Donna Neuberg, Ian W. Flinn, Michael R. Grever, Hillard M. Lazarus, Jacob M. Rowe, Gordon W. Dewald, John M. Bennett, Elisabeth Paietta, John C. Byr...> ;Blood. 2011 Sep 29
Long-term estimate of quality-adjusted life expectancy for nilotinib and imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-pos...
Botteman M, Stephens J, Snedecor SJ, Ji X, Hussein M, Coombs J> ;J. Clin. Oncol.. 2011-05-20
Changing characteristics and improved outcome of early breast cancer in low- and middle-income countries.
El-Saghir NS, Mikdachi H, Nachef Z, El Asmar N, Sibai H, Boulos F, Abbas J, Hussein M, Jamali F, Berjawi G, Bikhazi KJ, Eid T> ;J. Clin. Oncol.. 2011-05-20
56 citations
A review of the history, properties, and use of the immunomodulatory compound lenalidomide
Jerome B. Zeldis, Robert Knight, Mohamad A. Hussein, Rajesh Chopra, George W. Muller> ;Annals of the New York Academy of Sciences. 2011 Mar 1
157 citations
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
Jeffrey A. Zonder, John Crowley, Mohamad A. Hussein, Vanessa Bolejack, Dennis F. Moore, Brock F. Whittenberger, Muneer H. Abidi, Brian G.M. Durie, Bart Barlogie> ;Blood. 2010 Dec 23
13 citations
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.
Rachid Baz, Mehul Patel, Elizabeth Finley-Oliver, Daniel Lebovic, Mohamad A. Hussein, Kena C. Miller, Margaret Wood, Taimur Sher, Kelvin P. Lee, Asher A. Chanan-Khan> ;Leukemia & Lymphoma. 2010 Jun 10
109 citations
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma.
Mohamad A. Hussein, James R. Berenson, Ruben Niesvizky, Nikhil C. Munshi, Jeffrey Matous, Ronald Sobecks, Kate Harrop, Jonathan G. Drachman, Nancy Whiting> ;Haematologica. 2010 May 1
6 citations
Prediction of Response and Progression in Multiple Myeloma With Serum Free Light Chains Assay: Corroboration of the Serum Free Light Chain Response Definitions
Rami Khoriaty, Mohamad A. Hussein, Beth Faiman, Megan Kelly, Matt Kalaycio, Rachid Baz> ;Clinical Lymphoma, Myeloma & Leukemia. 2010 Feb 1
Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy.
Kim MH, Lin J, Hussein M, Battleman D> ;Curr Med Res Opin. 2009-12-01
1 citations
IMMUNOMODULATORY COMPOUNDS (IMIDS®) IN THE TREATMENT OF MULTIPLE MYELOMA
Gordan Srkalovic, Mohamad A. Hussein> ;Bosnian Journal of Basic Medical Sciences. 2009 Oct 20
131 citations
Vorinostat in solid and hematologic malignancies
David S. Siegel, Mohamad A. Hussein, Chandra P. Belani, Francisco Robert, Evanthia Galanis, Victoria M. Richon, Jose Garcia-Vargas, Cesar Sanz-Rodriguez, Syed Rizvi> ;Journal of Hematology & Oncology. 2009 Jul 27
130 citations
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Paul G. Richardson, Sundar Jagannath, Mohamad A. Hussein, James R. Berenson, Seema Singhal, David Irwin, Stephanie F. Williams, William I. Bensinger, Ashraf Badros, Ro...> ;Blood. 2009 Jul 23
Join now to see all

Abstracts/Posters

Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)
Mohamad A. Hussein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Starton Therapeutics Advances STAR-LLD Transdermal Lenalidomide Following Successful Skin Permeation StudiesJune 9th, 2021
Drs. Kenneth Anderson and Asher Chanan-Khan to Join Starton Therapeutics Board of DirectorsSeptember 9th, 2020
ChemioCare Strengthens Its Proposed Slate of Directors with the Nomination of Multiple Myeloma Expert Dr. Mohamad HusseinOctober 7th, 2019
Join now to see all